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Introduction: The recommended lower limit of intensity during continuous renal replacement therapy (CRRT) is
20 or 25 mL/kg/h. However, limited information is available to support this threshold. We aimed to evaluate the
impact of different intensities of CRRT on the clearance of creatinine and urea in critically ill patients with severe
acute kidney injury (AKI).
Methods: This is a multicenter retrospective study conducted in 14 Japanese ICUs in 12 centers. All patients older
than 18 years and treated with CRRT due to AKI were eligible. We evaluated the effect of CRRT intensity by two
different definitions: daily intensity (the mean intensity over each 24-h period) and average intensity (the mean
of daily intensity during the period while CRRT was performed). To study the effect of different CRRT intensity on
clearance of urea and creatinine, all patients/daily observations were arbitrarily allocated to one of 4 groups based
on the average intensity and daily intensity: <10, 10–15, 15–20, and >20 mL/kg/h.
Results: Total 316 patients were included and divided into the four groups according to average CRRT intensity.
The groups comprised 64 (20.3%), 138 (43.7%), 68 (21.5%), and 46 patients (14.6%), respectively. Decreases in creatinine
and urea increased as the average intensity increased over the first 7 days of CRRT. The relative changes of serum
creatinine and urea levels remained close to 1 over the 7 days in the “<10” group. Total 1,101 daily observations were
included and divided into the four groups according to daily CRRT intensity. The groups comprised 254 (23.1%), 470
(42.7%), 239 (21.7%), and 138 observations (12.5%), respectively. Creatinine and urea increased (negative daily change)
only in the “<10” group and decreased with the increasing daily intensity in the other groups.
Conclusions: The lower limit of delivered intensity to control uremia during CRRT was approximately between 10 and
15 mL/kg/h in our cohort. A prescribed intensity of approximately 15 mL/kg/h might be adequate to control uremia
for patients with severe AKI in the ICU. However, considering the limitations due to the retrospective nature of this
study, prospective studies are required to confirm our findings.Introduction
Acute kidney injury (AKI) occurs commonly in the ICU
and is associated with substantial morbidity and mortality
[1-6]. Continuous renal replacement therapy (CRRT) is a
preferred choice for critically ill patients, especially when
they are hemodynamically unstable. However, despite
improvements in CRRT techniques and the general
management of critically ill patients, the mortality of* Correspondence: yasudahideto@me.com
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unless otherwise stated.patients who require CRRT remains high at more than
40% [7-9].
A decade ago, CRRT intensity as high as 35 mL/kg/h
was recommended for critically ill patients with AKI to
improve mortality [10]. However, more recently, two
large randomized controlled trials have shown that there
is no advantage to high intensity CRRT (>35 mL/kg/h)
with regard to hospital mortality [7,9]. Based on these
results, 20 or 25 mL/kg/h has been recommended as the
lower limit of intensity during CRRT by the recent
KDIGO (Kidney Disease Improving Global Outcomes)
Clinical Practice Guideline [11]. However, limited infor-
mation is available to support this threshold and anLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Because the one of the aims of providing CRRT to critically
ill patients is to control uremia, very low intensity during
CRRT may not be acceptable if low molecular weight
solutes (for example, creatinine and urea) increase during
the procedure [18].
Previously, no studies have focused on the lower limit
of intensity sufficient to control uremia during CRRT
[19]. The Japanese Society of Education for Physicians and
Trainees in Intensive Care (JSEPTIC) CRRT database is a
multicenter retrospective study that aims to understand
multiple aspects of CRRT [13,20]. As part of the larger
study, we aimed to evaluate the impact of different inten-
sities of CRRT on the clearance of creatinine and urea in
critically ill patients with severe AKI.
Materials and methods
This is a multicenter retrospective study that was con-
ducted in 14 ICUs in 12 centers in Japan. The study proto-
col was reviewed and approved by the Ethics Committee or
Investigational Review Board of each participating center.
Ethics Committees in all centers waived the need for
written informed consent because data were collected
retrospectively.
Study population
All patients older than 18 years admitted to one of the
participating ICUs between January and December 2010
and treated with CRRT due to AKI according to the risk,
injury, failure, loss, end-stage renal failure (RIFLE) criteria
[21] were eligible. The following patients were excluded
from this study: patients aged less than 18 years, patients
with any renal replacement therapy (RRT) before ICU
admission, and patients with end-stage renal failure on
chronic dialysis. Patients with no information on their
body weight at ICU admission were also excluded because
their CRRT intensity could not be calculated. If a patient
was admitted to the ICU and treated with CRRT more
than once during the same hospital admission, only the
first ICU admission was included.
Data collection
The following data were obtained from case report forms:
age, gender, body weight (measured or estimated at ICU
admission based on the methods of each participating
center), date of hospital admission, date of ICU admission,
simplified acute physiology score (SAPS II) on the day
of ICU admission [22] and primary diagnosis. Factors
contributing to AKI were collected and categorized
according to the following list: septic shock, major
surgery, cardiogenic shock, hypovolemia, drug-induced,
or other. Multiple choices were allowed if necessary.
The following data were also collected at CRRT initi-
ation: use of vasopressors and mechanical ventilation,mean arterial pressure (MAP), arterial partial pressure
of oxygen/inspired oxygen fraction (PaO2/FiO2) ratio,
lactate, Glasgow coma scale (GCS), platelet count, bili-
rubin, diuretic use, urine output, CRRT mode (continuous
veno-venous hemofiltration (CVVH), continuous veno-
venous hemodialysis (CVVHD), continuous veno-venous
hemodiafiltration (CVVHDF)), and blood flow rate. Serum
creatinine and urea levels were collected at CRRT initi-
ation (day 1) and over the first 7 days of CRRT. Dates
and times of CRRT start and stop, and dialysate and
replacement flow rates were collected for each filter
over the first 7 days of CRRT. The CRRT dose was
defined as the sum of the dialysate and replacement
flow rates (mL/h) because all CVVH and CVVHDF
were performed with post-dilution. The CRRT intensity
was defined as the CRRT dose divided by body weight
(mL/kg/h). ICU and hospital mortality and RRT require-
ment at hospital discharge were also collected.
Definitions for CRRT intensity and creatinine/urea change
As this is a retrospective study, the CRRT dose was decided
by treating physicians and could have changed every day
according to patient conditions. We therefore evaluated the
effect of CRRT intensity by two different definitions: daily
intensity and average intensity. Daily intensity was defined
as the mean intensity over each 24-h period (from 6:00 AM
to 6:00 AM next day). For example, if CRRT was performed
at 15 mL/kg/h for 4 h and also at 10 mL/kg/h for 10 h in
one day (with a period of 10 h with no CRRT), the daily
intensity was calculated as:
15 mL=kg=h 4 hþ 10 mL=kg=h 10 hð Þ=24 h
¼ 6:7 mL=kg=h
Average intensity was defined as the mean of daily
intensity during the period while CRRT was performed
in the ICU.
Relative and daily creatinine/urea changes were calcu-
lated as follows:
Relative creatinine=urea changes ¼ Cday N=Cday 1
Daily creatinine=urea changes
¼ Cday N−Cday Nþ1
 
=Cday N
where Cday N is the concentration of creatinine or urea
on day N and Cday N+1 is the concentration of creatinine
on the next day.
Statistical analyses
Data are presented as medians and interquartile ranges
(25th to 75th percentiles) or percentages. To study the
effect of different CRRT intensities on clearance of
urea and creatinine, all patients/daily observations
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the average intensity (patients) and daily intensity (daily
observations): <10, 10 to 15, 15 to 20, and >20 mL/kg/h.
The Chi-square test was used for nominal variables and
the Kruskal-Wallis test was used for numerical variables
to compare differences among the four intensity groups.
All tests were two-tailed, and P-values <0.05 were consid-
ered statistically significant. All statistical analyses were
performed using a commercially available statistical pack-
age, JMP 10.0 (SAS Inc., Cary, NC, USA).
Results
During the study period, a total of 343 patients were
registered into the JSEPTIC database. Of these, 27 were
excluded because information on their body weight at
ICU admission and creatinine (or urea) one day after
starting CRRT (needed to calculate the daily intensity
and relative creatinine/urea changes) were not collected.
The remaining 316 patients were divided into four groups
according to the average CRRT intensity (<10, 10 to 15,
15 to 20, and >20). The groups comprised 64 (20.3%), 138
(43.7%), 68 (21.5%), and 46 patients (14.6%), respectively.
Patient demographics are shown in Table 1. The SAPS II
score increased (46 in the <10 group and 63 in the >20
group; P =0.02) and body weight decreased (68 kg inTable 1 Patient demographics
Avera
<10 (n =64) 10 to 15 (n =
Age, years 67 (53, 76) 69 (60, 76)
Gender, male 47 (73.4%) 93 (67.4%)
Weight, kg 68 (60, 79) 60 (52, 70)
SAPS II score 49 (37, 65) 52 (39, 64)
Premorbid creatinine, μmol/L 95 (70, 137) 93 (68, 177)
Postoperative admission 17 (26.6%) 48 (34.8%)
Diagnostic grouping
Cardiovascular 33 (51.6%) 65 (47.1%)
Gastrointestinal 12 (18.8%) 34 (24.6%)
Sepsis 7 (10.9%) 13 (9.4%)
Respiratory 8 (12.5%) 18 (13.0%)
Others 18 (28.1%) 32 (23.2%)
Contributing factors to AKI
Septic shock 22 (34.4%) 66 (47.8%)
Major surgery 20 (31.3%) 35 (25.4%)
Cardiogenic shock 28 (43.8%) 40 (29.0%)
Hypovolemia 11 (17.2%) 26 (18.8%)
Drugs 1 (1.6%) 7 (5.1%)
Others 10 (15.6%) 15 (10.9%)
Results are presented as median (IQR) or number (%). n, number of patients; SAPS Ithe <10 group and 50 kg in the >20 group; P <0.0001)
as the average intensity increased. Septic shock was
more common in the groups exhibiting a higher CRRT
intensity, and major surgery and cardiogenic shock
were more common in the groups exhibiting a lower
CRRT intensity.
Table 2 shows the patient characteristics at CRRT ini-
tiation and the outcomes in the four groups. There were
no significant differences in vital signs and laboratory data
(vasopressor use, MAP, mechanical ventilation, PaO2/FiO2
ratio, lactate, GCS, platelet count, bilirubin, urine output,
creatinine, and urea) between the four groups. The rate of
diuretic use increased as the average intensity decreased
(56.3% in the <10 group and 28.3% in the >20 group;
P =0.035). There was a significant difference in CRRT
dose (0.60 L/h in the <10 group and 1.3 L/h in the >20
group; P <0.0001) and average intensity (8.7 mL/kg/h
in the <10 group and 24.4 mL/kg/h in the >20 group;
P <0.0001) between the four groups. ICU and hospital
mortality were similar among the four groups (P =0.47
and 0.53, respectively).
Figure 1 shows relative changes in serum creatinine
(1a) and urea (1b) levels in the four groups over the first
7 days of CRRT. The decreases in creatinine and urea
increased as the average intensity increased. The relativege intensity, mL/kg/h
138) 15 to 20 (n =68) >20 (n =46) P-value
71 (58, 79) 71 (60, 77) 0.31
45 (66.2%) 22 (47.8%) 0.04
54 (50, 61) 50 (42, 60) <0.0001
52 (39, 68) 63 (50, 79) 0.02
88 (68, 157) 74 (55, 105) 0.17
29 (42.7%) 5 (10.9%) 0.002
26 (38.2%) 9 (19.6%) 0.003
15 (22.1%) 12 (26.1%) 0.77
11 (16.2%) 3 (6.5%) 0.36
11 (16.2%) 8 (17.4%) 0.83
21 (30.9%) 20 (43.5%) 0.28
37 (54.4%) 26 (56.5%) 0.07
17 (25.0%) 3 (6.5%) 0.02
10 (14.7%) 7 (15.2%) 0.0005
20 (29.4%) 14 (30.4%) 0.13
6 (8.8%) 5 (10.9%) 0.15
11 (16.2%) 13 (28.3%) 0.09
I, simplified acute physiology score II; AKI, acute kidney injury.
Table 2 Patient characteristics at CRRT initiation and outcomes
Average intensity, mL/kg/h
<10 10 to 15 15 to 20 >20 P-value
Vasopressor use 54 (84.4%) 92 (66.7%) 45 (66.2%) 32 (69.6%) 0.06
Mean arterial pressure, mmHg 73 (65, 84) 71 (60, 80) 73 (64, 83) 67 (57, 80) 0.23
Mechanical ventilation 53 (82.8%) 111 (80.4%) 58 (85.3%) 41 (89.1%) 0.55
PaO2/FiO2 ratio, Torr 215 (152, 300) 197 (136, 300) 226 (134, 331) 208 (125, 336) 0.83
Lactate, mmol/L 2.4 (1.5, 5.7) 2.5 (1.4, 5.2) 2.4 (1.4, 4.3) 3.4 (1.5, 8.0) 0.61
Glasgow coma scale 14 (11, 15) 14 (10, 15) 14 (9, 15) 12 (6, 15) 0.05
Platelet count, 103/μL 107 (59, 163) 90 (52, 142) 84 (51, 156) 88 (56, 154) 0.55
Bilirubin, mmol/L 20.5 (12.0, 54.7) 18.8 (10.3, 37.6) 15.4 (8.6, 40.6) 17.7 (8.6, 42.3) 0.26
Diuretics use 36 (56.3%) 62 (44.9%) 29 (42.7%) 15 (28.3%) 0.035
Urine output, mL/h 17 (5, 45) 21 (9, 40) 22 (9, 53) 16 (5, 42) 0.67
Creatinine, μmol/L 248 (159, 378) 242 (182, 328) 225 (163, 310) 254 (169, 363) 0.55
Urea, mmol/L 18.0 (11.7, 27) 17.7 (12.1, 25.8) 17.5 (10.7, 23.0) 20.0 (14.3, 35.3) 0.14
ICU to start, day 0.9 (0.2, 1.7) 0.9 (0.2, 2.0) 1.0 (0.2, 2.2) 0.4 (0.1, 1.7) 0.44
Mode of CRRT
CVVH 6 (9.4%) 7 (5.1%) 1 (1.5%) 4 (8.7%) 0.19
CVVHD 24 (37.5%) 33 (23.9%) 9 (13.2%) 8 (17.4%) 0.008
CVVHDF 34 (53.1%) 98 (71.0%) 58 (85.3%) 34 (73.9%) 0.0008
Blood flow, mL/min 100 (80, 100) 100 (80, 100) 100 (80, 100) 100 (80, 100) 0.89
CRRT dose, L/h 0.60 (0.60, 0.80) 0.80 (0.60, 0.8) 1.0 (0.8, 1.0) 1.3 (1.0, 3.0) <0.0001
Average intensity, mL/kg/h 8.7 (7.1, 9.2) 12.6 (11.1, 13.9) 16.6 (15.7, 18.3) 24.4 (20.9, 30.9) <0.0001
CRRT down time (%) 5.8 (0, 21.3) 1.5 (0, 6.2) 2.6 (0.4, 5.2) 1.5 (0, 4.0) 0.014
CRRT duration, days 3.9 (1.9, 6.9) 3.3 (1.7, 6.1) 2.7 (1.7, 5.6) 2.6 (1.3, 4.8) 0.36
ICU mortality 30 (46.9%) 57 (41.3%) 24 (35.3%) 22 (47.8%) 0.47
Hospital mortality 35 (54.7%) 76 (55.1%) 35 (51.5%) 30 (65.2%) 0.53
RRT at discharge among survivors 7 (24.1%) 6 (9.7%) 3 (9.1%) 0 (0%) 0.09
Results are presented as number (%) or median (IQR), ICU to start, duration between ICU admission to continuous renal replacement therapy (CRRT) initiation;
CVVH, continuous veno-venous hemofiltration; CVVHD: continuous veno-venous hemodialysis; CVVHDF, continuous veno-venous hemodiafiltration; RRT, renal
replacement therapy.
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close to 1 over the 7 days in the <10 group.
During the study period, a total of 1,101 daily observa-
tions were conducted in 339 patients. These observations
were divided into four groups according to the daily CRRT
intensity (<10, 10 to 15, 15 to 20, and >20). The groups
comprised 254 (23.1%), 470 (42.7%), 239 (21.7%), and 138
observations (12.5%), respectively. Figure 2 shows the daily
changes of serum creatinine (2a) and urea (2b) levels in the
four groups. Creatinine and urea increased (negative daily
change) only in the <10 group and decreased with the
increasing daily intensity in the other groups.
The analyses shown in Figures 1 and 2 were repeated
for patients who had sepsis/septic shock (n =151 for aver-
age intensity and n =665 for daily intensity) for sensitivity
analysis. Findings of these analyses are essentially similar
to the analyses for all patients (only intensity <10 ml/kg/h
had poor control for urea and creatinine).Discussion
Key findings
In this study, we have evaluated the impact of different
delivered intensities of CRRT on the control of serum
creatinine and urea in critically ill patients with severe
AKI. We analyzed CRRT intensity by two different defini-
tions: daily intensity and average intensity. Both analyses
found that the lower limit of intensity necessary to control
uremia during CRRT was approximately between 10 and
15 mL/kg/h in our cohort.
Relationship to previous studies
Many studies have been conducted in an attempt to
improve the outcome of AKI patients in the ICU
[7,9,10,23-31]. Increasing the CRRT intensity is one of
the methods used, and several studies have noted the
effects of high intensity CRRT [7,9,10,14,15,29]. However,



















































Figure 1 Relationship between the average continuous renal
replacement therapy (CRRT) intensity and relative changes in
creatinine (a) and urea (b) over seven days from the start of
CRRT. Patients were grouped on the basis of the average intensity
(patients) and daily intensity (daily observations) as follows: below 10
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a
Figure 2 Relationship between daily continuous renal replacement
therapy (CRRT) intensity and daily changes of creatinine (a) and
urea (b). Patients were grouped on the basis of the average intensity
(patients) and daily intensity (daily observations) as follows: below 10
(<10), 10 to 15 (10-15), 15 to 20 (15-20), and above (>20) mL/kg/h.
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intensity therapy (>35 mL/kg/h) compared with lower in-
tensity (20 to 25 ml/kg/h) [7,9]. Two recent meta-analyses
have also shown similar results [28,29]. According to these
results, the recent KDIGO Clinical Practice Guideline
recommended delivering an effluent volume of 20 to
25 ml/kg/h. They also recommended prescribing in the
range of 25 to 30 ml/kg/h in order to achieve a delivered
dose of 20 to 25 ml/kg/h. [11]. However, although current
evidence seems adequate for recommending the upper
limit of CRRT intensity, only limited information is avail-
able to support the lower intensity limit. Indeed, there has
been no randomized controlled study comparing CRRT
intensity lower than 20 to 25 ml/kg/h and only a few
observational studies have looked at this issue [12,13,28].
For example, in our previous study [13], we compared
high- and low-intensity therapy using our database (JSEP-
TIC) and the Beginning and Ending Supportive Therapy
for the Kidney (BEST kidney) database [2]. Although
CRRT intensity was lower in our database (14.3 mL/kg/h)compared with that of the BEST kidney database (20.4 mL/
kg/h, P <0.001), patients in the JSEPTIC database tended
to have lower hospital mortality (58.6% versus 64.2%,
P =0.070) compared with the BEST study.
As the one of aims of performing CRRT is to control
uremia, low-intensity therapy may be thought inadequate
and unacceptable when low molecular-weight solutes
increase during CRRT. Urea and creatinine, clinically
measured low molecular-weight solutes, are commonly
used as surrogate markers for the toxic metabolites of
renal failure. However, no previous studies have evaluated
the impact of different CRRT intensity on controlling
uremia. In Japan, replacement/dialysis fluid use of only 10
to 16 mL/kg/h (15 to 24 L/day) is allowed because of
the Japanese medical insurance system. Therefore, using
our database collected in 14 Japanese ICUs, we studied
for relationship between different CRRT intensity and
serum creatinine/urea control. As this is a retrospective
study and the CRRT dose could have changed every
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effect of CRRT intensity by two different definitions: daily
intensity and average intensity. Both analyses found that
creatinine and urea increased only in the <10 group and
decreased with the increasing intensity in the other
groups. From our findings, delivered CRRT intensity of
around 10 to 15 mL/kg/h seems to be the lower limit to
control uremia.
Significance and implications
Conducting CRRT is not without complications. Unneces-
sarily high-intensity CRRT could lead to electrolyte abnor-
malities such as hypophosphatemia and hypomagnesemia,
frequent machine troubles, and inadequate drug adminis-
tration, especially antibiotics. Therefore, seeking the lower
limit of CRRT intensity seems clinically important.
Furthermore, the advantage of lower intensity CRRT
is also related to the economic problem of CRRT. It is
reported that the cost of CRRT is higher than that of
intermittent hemodialysis (IHD) [32], and the cost of
higher-intensity CRRT is more than that of lower-intensity
CRRT because of the greater volume of replacement/dialy-
sis fluid required [33,34]. This high cost can have a major
impact, particularly on low- or middle-income countries.
Strengths and limitations
There are several strengths in this study. As far as we
know, this is the first study to evaluate the effect of
different CRRT intensity on solute control. We were able
to conduct such an evaluation because it is common
to perform low-dose CRRT in Japan and we rarely see
difficulty in small solute control in our patients with
severe AKI requiring CRRT. Another strength of this
study is that we collected information for each filter
and evaluated the delivered dose of CRRT, not the pre-
scribed dose. In clinical practice, delivery usually falls
substantially short of the prescribed dose. Although it
has been reported that on average the delivered dose
is approximately 80% of the prescribed dose [10,21],
such a shortfall can be quite varied day to day and
among patients. Using the delivered dose in our study
should provide more accurate evaluation of the effect
on daily solute control.
There are also several limitations to our study. First,
this is a retrospective observational study with a relatively
small sample size, which inevitably contains various
biases, including differences in patient background and
decision-making about prescribed CRRT intensity by a
treating physician. For example, it is likely that the
CRRT dose was often prescribed regardless of patient
body weight. Also, in many cases, the CRRT intensity was
between 10 and 15 mL/kg/h because of the Japanese
medical insurance system. This resulted in a smaller
number (approximately one third) of patients in thehigher-intensity group (>20 mL/kg/h) compared with
that in the lower-intensity groups (10 to 15 mL/kg/h).
Second, the CRRT intensity was calculated using body
weight measured or estimated at ICU admission based on
methods that differed between the participating centers.
The accuracy of body weight measurements may also have
been affected by patient’s condition before ICU admission,
such as differences in fluid balance and protein catabol-
ism. Third, serum creatinine and urea levels depend on
the balance between the body’s production, amount of
fluid balance/hemodilution and clearance by CRRT and
the kidneys. We did not collect information on small
solute clearance from residual kidney function and daily
body fluid balance, and therefore, we might have over-
estimated (or underestimated) creatinine/urea changes
at some time points or in some patients. Finally, and
most importantly, we did not evaluate the relationship
between CRRT intensity and mortality/morbidity, such as
renal recovery, weaning of vasopressors and mechanical
ventilation, ICU and hospital length of stay. With all the
limitations and drawbacks of this study, we cannot recom-
mend to the ICU medical community to routinely use 10
to 15 mg/kg/h.
Conclusions
In this study for the first time in the literature, we have
evaluated the impact of different intensities of CRRT on
the control of serum creatinine and urea in critically ill
patients with severe AKI. We found that the lower limit
of intensity to control uremia during CRRT was approxi-
mately between 10 and 15 mL/kg/h in our cohort. A
prescribed intensity of approximately 15 mL/kg/h might
be adequate to control uremia for patients with severe
AKI in the ICU. This issue is important to avoid side
effects of CRRT and reduce costs, particularly in low- or
middle-income countries. However, considering the limi-
tations due to the retrospective nature of this study, pro-
spective studies are required to confirm our findings.
Key messages
 The lower limit of intensity to control uremia
during CRRT seemed to be approximately between
10 and 15 mL/kg/h
 A prescribed intensity of approximately 15 mL/kg/h
might be adequate to control uremia for patients
with severe AKI in the ICU
 To determine the lower limit of intensity to control
uremia during CRRT is important to avoid side
effects of CRRT and reduce costs, particularly in
low- or middle-income countries
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